定量Delta T1(dT1)作为替代美国放射学院影像网络6677/放射治疗肿瘤学组0625多中心脑肿瘤试验中集中裁决的中央读者分析对比增强肿瘤负荷的亚分析
本研究为ACRIN 6677/RTOG 0625多中心随机II期贝伐珠单抗治疗复发性胶质母细胞瘤试验的回顾性亚分析,比较定量dT1图与2D手动勾画对比增强肿瘤在预测进展和总生存方面的表现。结果显示dT1与集中裁决的2D手动勾画在读片者间一致性上,第8周完全一致,第16周为73.7%;dT1可能为临床试验节省大量时间和成本。
要点
- dT1与集中裁决的2D手动勾画在识别进展时第8周完全一致,第16周一致性为73.7%。
- 两种方法在各时间点均显示总生存期存在显著差异。
- dT1可能为临床试验节省大量时间和成本。
核心结论
- dT1可预测早期进展,与标准方法相当,并可能为临床试验节省大量时间和成本。
研究设计与样本
- ACRIN 6677/RTOG 0625多中心随机II期贝伐珠单抗治疗复发性胶质母细胞瘤试验的回顾性亚分析;来自23家机构的123例患者,第8周(n=74)和第16周(n=57)的2D手动勾画和dT1数据集均可评估;参考标准为集中裁决的2D手动勾画对比增强肿瘤读片。
诊断标准与关键数值
- 识别进展时,dT1与集中裁决的2D手动勾画读片在第8周完全一致,第16周一致性为73.7%。
- 将无进展者进一步分为应答者与无应答/无进展者时,一致性降至70.3%和52.6%。
- dT1在第8周显示总生存期存在显著差异(P = .01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Brain tumor clinical trials requiring solid tumor assessment typically rely on the 2D manual delineation of enhancing tumors by ≥2 expert readers, a time-consuming step with poor interreader agreement. As a solution, we developed quantitative dT1 maps for the delineation of enhancing lesions. This retrospective analysis compares dT1 with 2D manual delineation of enhancing tumors acquired at 2 time points during the post therapeutic surveillance period of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 (ACRIN 6677/RTOG 0625) clinical trial.
MATERIALS AND METHODS: Patients enrolled in ACRIN 6677/RTOG 0625, a multicenter, randomized Phase II trial of bevacizumab in recurrent glioblastoma, underwent standard MR imaging before and after treatment initiation. For 123 patients from 23 institutions, both 2D manual delineation of enhancing tumors and dT1 datasets were evaluable at weeks 8 (n = 74) and 16 (n = 57). Using dT1, we assessed the radiologic response and progression at each time point. Percentage agreement with adjudicated 2D manual delineation of enhancing tumor reads and association between progression status and overall survival were determined.
RESULTS: For identification of progression, dT1 and adjudicated 2D manual delineation of enhancing tumor reads were in perfect agreement at week 8, with 73.7% agreement at week 16. Both methods showed significant differences in overall survival at each time point. When nonprogressors were further divided into responders versus nonresponders/nonprogressors, the agreement decreased to 70.3% and 52.6%, yet dT1 showed a significant difference in overall survival at week 8 (P = .01), suggesting that dT1 may provide greater sensitivity for stratifying subpopulations.
CONCLUSIONS: This study shows that dT1 can predict early progression comparable with the standard method but offers the potential for substantial time and cost savings for clinical trials.
引用
- Schmainda KM, Prah MA, Zhang Z, et al. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. AJNR Am J Neuroradiol. 2019. PMID: 31248863. doi:10.3174/ajnr.A6110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。